Update upon efficacy and safety of P01375 -α inhibitors . The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments . Among these , tumor necrosis factor ( P01375 ) -α inhibitors , that is , infliximab , adalimumab , etanercept , DB06674 and certolizumab pegol , are now available for clinical use . This editorial discusses the recent indications of P01375 -α inhibitors , the pretreatment considerations , the reported adverse events and , finally , the recommendations for its use in pregnancy .